NewsRelease
PatentApplication Highlights AlbuVoid™ in Cell-based Drug Toxicity Assays
MONMOUTHJUNCTION, NJ,October15, 2019 -- Biotech Support Group reports on a new patent applicationwhich highlights the simplicity and efficiency of their Albumindepletion sample preparation technology as an enrichment step forserum containing medium used in cell culture for LC-MS proteomicanalysis. The citation is:
Narain,Niven Rajin, Rangaprasad Sarangarajan, and Vivek K. Vishnudas."Interrogatory cell-based assays for identifying drug-inducedtoxicity markers." U.S. Patent Application No. 16/180,446.
Thelack of reliable tools that can help with predicting toxicity earlyin drug development is partly to blame for a 90% attrition ofpotential compounds entering clinical development, 30% of which isowing to poor clinical safety. Cardiotoxicity particularly is aleading cause of drug withdrawal. The invention described is usefulfor identifying markers associated with drug-induced toxicity. Thepatent application states “Inone embodiment, the cells can be cultured in serum containing medium:The volume of the medium can be reduced using 3 k MWCO Vivaspincolumns (GE Healthcare Life Sciences), then can be reconstituted with1×PBS (Invitrogen). Serum albumin can be depleted from all samplesusing AlbuVoid column (Biotech Support Group, LLC) following themanufacturer's instructions with the modifications of buffer-exchangeto optimize for condition medium application.” The patentdescription includes a novel, collaborative utilization of networkbiology, genomic, proteomic, metabolomic, transcriptomic, andbioinformatics tools and methodologies, which, when combined, may beused to study any biological system of interest, such as obtaininginsight into the molecular mechanisms associated with or causal fordrug-induced toxicity.
“Iare very pleased to see that AlbuVoid™ was referenced for theproteomic analysis of cell culture. As we do not use immunoaffinity,separations are efficient across all species” states Swapan Roy,Ph.D., President and Founder of Biotech Support Group.
Formore information onAlbuVoid™,go to:http://www.biotechsupportgroup.com/AlbuVoid-Albumin-Depletion-and-Low-Abundance-p/avk.htm
Formore information on the BSG complete line ofAlbumin& IgG Removal products,visit:https://www.biotechsupportgroup.com/Articles.asp?ID=451
AboutBiotech Support Group LLC
Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ for lipidadsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal,and NuGel™ for functional proteomics. From these innovations, thecompany has acquired knowledgebase and biomarker intellectualproperty assets that support discoveries of protein markers fromblood, with special emphasis on early detection and personalizedmedical decisions for cancer patients. For more information, gotohttp://www.biotechsupportgroup.com.
Contact:
MatthewKuruc 732-274-2866,
[email protected]